Andera Partners

EG 427 is a French biotechnology company that specializes in a novel approach to gene therapy known as pinpoint gene therapy. The company focuses on developing HSV-1-based vectors, leveraging the natural characteristics of Herpes Simplex Virus 1 to create targeted and long-lasting expression of therapeutic genes. This innovative method aims to address spinal cord injury-related disorders, particularly neurogenic bladder conditions, by providing physicians with a potential cure for patients suffering from severe, chronic, and localized diseases. Through its advanced research, EG 427 seeks to transform treatment options for individuals affected by these challenging medical issues.

Ayming is a management consulting firm headquartered in Levallois, France, that focuses on optimizing operational performance for its clients. The company provides a range of services, including consulting on human resources costs, tax strategies, operational costs optimization, software solutions, and energy and environmental issues. Additionally, Ayming offers advisory services related to work contributions and wage audits. By leveraging these diverse consulting offerings, Ayming aims to help organizations enhance their efficiency and overall performance while effectively managing social costs associated with taxes and financial operations.

Bioptimus is a biotechnology company focused on developing a universal artificial intelligence foundation model that integrates various scales of biology, from molecules to cells, tissues, and entire organisms. The company's innovative technology leverages generative AI to transform complex multiscale biological data into actionable insights, facilitating significant advancements in scientific research and biomedical innovation. By enabling clients to effectively harness this data, Bioptimus aims to drive breakthrough discoveries and enhance the efficiency of biotechnological processes.

Qovoltis operates in the renewable energy sector, focusing on smart charging solutions for electric vehicles. The company has developed a smart charger that adapts to real-time power demand and is compatible with vehicles adhering to the ISO 15118 standard. In addition to the charging hardware, Qovoltis offers a mobile application that enables users to authenticate their identities and manage their charging sessions remotely. Furthermore, the company provides innovative charging station solutions tailored for real estate developments, aimed at enhancing the value of these properties. Qovoltis’s comprehensive offerings include installation services for charging points and terminals, real-time supervision of charging operations, and competitive pricing for electricity supply.

Skysun is a financial institution that provides financial solutions and services to the solar energy sector.

Kestra Medical Technologies, Inc. is a company that specializes in developing and manufacturing wearable medical devices aimed at monitoring and managing acute medical conditions. Founded in 2014 and headquartered in Kirkland, Washington, the company offers solutions that enable the collection, communication, and storage of patient performance data, facilitating both real-time and retrospective analysis. Among its key products are wearable cardioverter defibrillators designed to prevent sudden cardiac death and aid in the recovery of at-risk cardiac patients. By focusing on intuitive and mobile diagnostic and therapeutic technologies, Kestra Medical Technologies strives to enhance patient care and support healthcare teams in effectively managing patient health.

SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2014 by scientists from the Infectiology Research Center. The company focuses on drug discovery and development for the treatment of acute and chronic viral infections, utilizing a unique platform to identify intracellular therapeutic targets and molecules. ENYO Pharma is developing a pipeline of drug candidates addressing various indications, including hepatitis B virus, nonalcoholic steatohepatitis, and oncology. Its lead compound, EYP001, is designed to modulate specific nuclear receptors, aiming to reduce viral reservoirs and inhibit harmful viral protein expression. The company is also advancing EYP002 through preclinical studies. ENYO Pharma collaborates closely with established research institutions and aims to conduct its molecules into Phase II clinical trials, striving to become a global leader in antiviral therapeutics.

Mylight150 contributes to the creation of a society in which people generates own electricity to ensure self-sufficiency and long-term abundance.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates engineered viral vector vaccines for cancer treatment. The company's innovative platform leverages a portfolio of modified viral vectors, specifically designed for the efficient expression of long strings of tumor neoantigens. This approach is complemented by a toolkit that facilitates the induction of robust antitumor T-cell responses, effectively enhancing cancer-specific cellular immunity in patients. Through its research and development efforts, Nouscom aims to improve cancer treatment outcomes by harnessing the body's immune system to target and combat cancer cells.

Qualisteo SAS, founded in 2010 and based in Nice, France, specializes in energy efficiency monitoring technology. The company has developed Wattseeker, a software tool that tracks and analyzes the electrical consumption of buildings, itemizing usage by specific equipment and zones. This technology aids enterprises in auditing their energy consumption, optimizing their environmental footprint, and reducing electricity costs. Through its offerings, Qualisteo enables businesses to effectively measure and manage their electricity usage, contributing to overall energy savings and enhanced operational efficiency.

Kepler Consulting is a business management consulting firm that serves various industries, including automotive, capital goods, aviation, and consumer products. The company focuses on enhancing productivity and maximizing operating profits for its clients through expertise in innovation, purchasing, supply chain management, marketing, sales, and operations. By offering tailored solutions, Kepler Consulting aims to improve efficiency and optimize operating margins for a diverse range of clients, including those in the public sector, luxury, retail, distribution, and service sectors, as well as in the automotive and cosmetics industries.

Crescendo Biologics Limited is a clinical-stage biotechnology company based in Cambridge, United Kingdom, specializing in the development of innovative therapies for oncology and dermatology. The company focuses on creating multi-specific immune-oncology modulators and Humabody Drug Conjugates using its proprietary transgenic mouse platform. This technology allows for the in vivo maturation of human VH domains, optimizing their affinity and biophysical properties for therapeutic use. Crescendo Biologics aims to address critical challenges in generating high-affinity, soluble human VH antibody fragments, which are recognized for their potential as effective therapeutics. By leveraging its advanced platforms, the company is engaged in the product development of in-house targets as well as collaborations with other organizations to enhance the efficacy of cancer treatments. Founded in 2007 and originally known as Translocus Limited, Crescendo Biologics has established itself as a leader in the field of next-generation antibody therapeutics.

Dualyx is a biotechnology company focused on the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company specializes in the creation of immune modulators, particularly Treg-targeted therapies, which are designed to suppress undesirable autoimmune responses in patients. Through its innovative approach, Dualyx aims to provide lasting treatments that offer potential cures for those suffering from autoimmune conditions.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

Ariceum Therapeutics is a clinical-stage radiopharmaceutical company that focuses on the detection and targeted treatment of aggressive cancers, particularly neuroendocrine tumors and other challenging malignancies. The company's lead product, 177Lu-satoreotide tetraxetan (Satoreotide), acts as an antagonist of the somatostatin type 2 receptor (SSTR2), which is commonly overexpressed in many neuroendocrine tumors. Ariceum is developing Satoreotide as a theranostic pair, which allows for both the diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, certain aggressive tumors, and childhood cancers. This approach aims to provide treatment options for conditions that currently have limited therapies and poor prognoses, enabling healthcare professionals to deliver more effective treatments with reduced side effects.

BioVentrix, Inc. is a medical device company based in San Ramon, California, that specializes in innovative treatments for congestive heart failure (CHF), particularly in patients with ischemic cardiomyopathy. Founded in 2003, the company has developed the Revivent Myocardial Anchoring System, which utilizes a hybrid closed-chest transcatheter procedure to enhance cardiac function. This device operates by restoring the size and volume of the left ventricle through the implantation of micro-anchoring pairs that effectively exclude scarred myocardium from healthy tissue. BioVentrix aims to provide less invasive, catheter-based solutions to improve patient outcomes and slow the progression of CHF, addressing a critical need in cardiac care.

Andera Partners, established in 2001, is a Paris-based private equity firm with a 250-year heritage tracing back to the Rothschild family. The firm manages over €2 billion, focusing on investments in unlisted companies across France and internationally. Andera Partners specializes in life sciences, growth capital, and sponsorless mezzanine debt, aiming to create long-term value for its investors.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

SoniVie is a medical device company focused on developing innovative solutions for the treatment of pulmonary hypertension. The company has created a minimally invasive denervation device that is designed to be inserted into the pulmonary artery through a catheterization procedure. This advanced technology selectively targets and damages the nerves associated with pulmonary hypertension, while preserving the integrity of the vessel walls and surrounding tissues. By enabling physicians to perform denervation procedures with greater precision, SoniVie aims to improve treatment options and outcomes for patients suffering from this serious condition.

Senstronic is an automotive company specializing in the design and manufacture of detection-based solutions and connectors tailored for control equipment in various vehicles. The company provides a diverse range of sensors, including inductive, magnetic, and capacitive proximity sensors, as well as optic-electronic sensors and splitting systems. These products are engineered for high resistance and reliability, making them suitable for not only the automotive industry but also for applications in aeronautics, railways, and agricultural machinery. By offering innovative detection solutions, Senstronic aims to address complex challenges faced by clients, ultimately enhancing their return on investment.

Qovoltis operates in the renewable energy sector, focusing on smart charging solutions for electric vehicles. The company has developed a smart charger that adapts to real-time power demand and is compatible with vehicles adhering to the ISO 15118 standard. In addition to the charging hardware, Qovoltis offers a mobile application that enables users to authenticate their identities and manage their charging sessions remotely. Furthermore, the company provides innovative charging station solutions tailored for real estate developments, aimed at enhancing the value of these properties. Qovoltis’s comprehensive offerings include installation services for charging points and terminals, real-time supervision of charging operations, and competitive pricing for electricity supply.

TRiCares is a medical device company focused on creating innovative solutions for tricuspid valve regurgitation. The company specializes in developing a catheter-based valve replacement system that facilitates minimally invasive treatments for patients suffering from tricuspid insufficiency. By emphasizing anatomical conformation and user-friendly design, TRiCares aims to provide effective and durable treatment options that improve patient outcomes. Through its advancements in medical technology, TRiCares addresses a critical need in cardiology, enhancing the quality of care for those affected by this condition.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Resonance Imaging Group is a medical imaging company based in Franconville, France, dedicated to providing comprehensive access to advanced imaging services for patients. The company specializes in a range of imaging modalities, including neuroimaging, oncology imaging, chest imaging, thyroid imaging, urinary imaging, virtual colonoscopy, and visceral imaging. By operating a network of medical imaging centers equipped with state-of-the-art technology, Resonance Imaging Group facilitates precise diagnoses, enhancing the ability of healthcare professionals to evaluate and treat various medical conditions effectively.

HR Path is a global consultancy focused on human capital management, with a team of over 500 consultants operating across North America, Europe, and the Middle East. The company specializes in HR Systems Integration, HR Outsourcing, and HR Business Consulting, offering a range of services to support businesses in their digital transformation. HR Path is an authorized reseller of various HR software solutions, including those from SAP, SuccessFactors, and Oracle HCM, among others. In addition to reselling, the company has developed its own HR software solutions, such as BiHRdy, a business intelligence tool; Pandore, a packaged HR, payroll, and time management solution; and Geef, a talent management system. The client portfolio includes a mix of large corporations, including CAC 40-listed companies, as well as small and medium-sized enterprises and public sector organizations, reflecting its versatility in meeting diverse client needs.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

ERI is a provider of electrical and technical engineering services, serving both private and public project owners in the construction and industrial sectors. The company specializes in the installation of various electrical and telecommunications equipment, including high and low-voltage systems, technical cabling, and optical fibers. In addition to its installation services, ERI offers expertise in climate engineering, as well as construction, renovation, and routine maintenance. This comprehensive approach allows ERI to support its clients across all facets of the construction industry, ensuring that their technical needs are met with precision and reliability.

Kyotherm is an investment company focused on financing renewable heat production and energy efficiency projects. It provides third-party financing to a range of stakeholders, including energy service providers, engineering firms, developers, heat consumers, and equipment manufacturers. By specializing in equity investment services, Kyotherm supports the development of energy infrastructures such as geothermal and biomass heating plants and district heating networks. The company aims to facilitate the acquisition of project capital, enabling clients to enhance the contractual and financial structuring of their energy initiatives. Through its expertise, Kyotherm plays a crucial role in advancing sustainable energy solutions.

TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.

Lhyfe is a French company founded in 2017 and based in Nantes, specializing in the design, development, and operation of industrial sites for the production of green hydrogen derived from renewable energy sources such as wind and solar power. The company focuses on creating sustainable and flexible production facilities that provide substantial quantities of clean hydrogen, aimed at facilitating the transition of various industrial sectors and transportation to a clean energy framework. Lhyfe targets two primary markets: heavy mobility, which includes trucks, buses, trains, and potentially maritime and air transport in the future, and industrial sectors such as chemistry, steel, and glass production, which are significant contributors to greenhouse gas emissions. By ensuring minimal environmental impact, Lhyfe is committed to delivering affordable green hydrogen to support a sustainable energy transition.

ImmoCity provides real estate investment and management services for both individuals and institutions or private companies. Their services include asset management, compelling investment opportunities, investment discipline, alignment of interests, strategic and institutional risk management compliance, and enabling clients to access proper mediums for their investment and expansion.

Exciva GmbH, founded in 2015 and headquartered in Heidelberg, Germany, focuses on developing innovative therapies for dementia and related diseases. The company operates a targeted drug rescue program aimed at pharmaceutical research and development, specifically designed to create symptomatic and disease-modifying treatments. Exciva specializes in addressing both the neurological and psychological aspects of behavioral and psychological symptoms associated with dementia. Its approach involves rescuing and repurposing approved drugs for new indications and uses, thereby providing valuable solutions to the healthcare industry. Through its comprehensive program, Exciva seeks to improve treatment options and outcomes for patients suffering from dementia.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

MC2-Technologies specializes in the development of innovative equipment designed to protect sensitive sites and infrastructures. The company focuses on manufacturing advanced microwave amplifiers and employs expertise in microwave frequencies and nanotechnologies. Its offerings include the characterization, modeling, and design of microwave components and devices. By serving clients in the defense, security, and telecommunications sectors, MC2-Technologies enables effective protection solutions tailored to the needs of these industries.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Atlantic Therapeutics Limited is a medical technology company based in Galway, Ireland, with additional offices in London, Paris, and Salem. Established in 2013, the company specializes in the manufacture and distribution of medical devices designed for pelvic floor muscle strengthening and nerve stimulation. Its key products include Innovotherapy, a device aimed at enhancing pelvic floor muscle function, and INNOVO, a wearable device specifically targeting stress urinary incontinence by addressing its underlying causes. Atlantic Therapeutics distributes its products through a network of distributors across Ireland, the United Kingdom, France, Germany, and the Middle East. The company operates as a subsidiary of Bio-Medical Research Limited.

MedLumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company develops integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method that offers detailed sectional information about tissue. MedLumics' radiofrequency cardiac ablation system provides real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation enhances procedural safety, reduces technical complexity, and lowers recurrence rates for patients undergoing treatment.

Sogetrel, S.A.S. is a prominent company specializing in the design, deployment, and maintenance of network infrastructures and digital communication solutions. Established in 1985 and headquartered in Issy les Moulineaux, France, Sogetrel operates branches in Belgium and Switzerland. The company provides a range of services, including the integration of telecommunications networks, IP security systems for video surveillance and access control, and support for smart city projects. Sogetrel serves a diverse clientele across various sectors such as telecommunications, public authorities, defense, transport, and utilities. By focusing on the development of very high-speed networks and offering both customized and turnkey solutions, Sogetrel aims to enhance the quality of life for citizens while promoting efficiency and sustainability in the regions it serves.

Sirsa, established in 2014 and based in Paris, France, is a consulting firm focused on sustainable transformation. The company specializes in evaluating existing processes and analyzing risks to define strategies for transforming operations. Sirsa offers a comprehensive suite of services that includes implementing strategic plans, managing action plans, reporting results, and providing compliance services. The firm caters to a diverse range of industries, including aerospace, defense, food products, electrical equipment, healthcare, energy, medical supplies, environmental, and software sectors. In addition, Sirsa has developed a software-as-a-service (SAAS) platform that measures companies' extra-financial footprint and impacts, further enhancing its commitment to sustainability and operational effectiveness.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Arvelle Therapeutics GmbH is a biopharmaceutical company headquartered in Zug, Switzerland, founded in 2019. The company is dedicated to developing and commercializing innovative treatments for patients suffering from central nervous system (CNS) disorders. Its primary focus is on cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients experiencing focal seizures. Through its efforts, Arvelle Therapeutics seeks to enhance the quality of care available to individuals affected by debilitating neurological and neuromuscular diseases.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

MasterGrid is a manufacturer and supplier of high-voltage electrical equipment based in Grenoble, France. Incorporated in 2019, the company, formerly known as Merlin Gerin, specializes in producing a range of products for the commercial and industrial sectors, including high, medium, and low-voltage equipment. MasterGrid focuses on the distribution, protection, control, and management of electrical systems, providing solutions that ensure safe and durable performance. In addition to its manufacturing capabilities, the company offers equipment handling services to meet the specific needs of its clients.

Olaqin is a healthcare service provider based in Suresnes, France, specializing in e-health solutions for healthcare professionals. The company distinguishes itself by offering tailored services to various sectors within the healthcare industry. Olaqin operates through a value-added distribution network, supplying SESAM-Vitale readers and associated software indirectly, while also engaging directly with hospitals and pharmacies via public and service contracts. Its offerings include centralized payment systems, securing electronic care sheets, updating Vitale cards, and ensuring secure access to online medical records. These services enhance operational efficiency for healthcare professionals by providing essential technological and management support.

Inotrem S.A. is a biotechnology company focused on developing innovative immunotherapies for acute and chronic inflammatory conditions. The company specializes in targeting the TREM-1 pathway to modulate unbalanced inflammatory responses. Inotrem's proprietary technology platform has led to the creation of nangibotide (LR12), a first-in-class TREM-1 inhibitor with potential applications in critical medical situations such as septic shock and myocardial infarction. Additionally, Inotrem is advancing research on new therapeutic modalities aimed at addressing chronic inflammatory diseases. By leveraging its expertise in immunomodulation, Inotrem aims to provide effective treatments for patients suffering from various inflammatory syndromes, enhancing critical care solutions in healthcare.

Ellisphere is a business intelligence company that provides decision-making information to executives and decision-makers in France and internationally through its BIGnet network. The company offers a comprehensive platform that delivers economic and financial information about trading partners, as well as insights into customer and supplier portfolios. Additionally, it provides guidance on legislation and regulatory compliance, helping businesses to develop effective customer-base strategies. By focusing on information management and data marketing, Ellisphere supports organizations in promoting and sustaining their growth and development.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

99 Advisory is a banking and insurance sectors are facing radical changes in their environments.

Travelsoft is a company focused on developing software solutions for the travel industry. It offers a Software-as-a-Service platform called Orchestra, which enables tourism professionals to create, manage, distribute, and administer leisure travel packages. The platform facilitates the distribution of various travel components, including journey packages, hotels, and flights, allowing users to manage their offerings across multiple distribution channels effectively. Through its innovative tools, Travelsoft aims to enhance the operational efficiency and reach of travel professionals in the leisure sector.

Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.

Spherea is a French company that manufactures and supplies testing solutions for electrical applications across various industries. Their product range includes model-based testing tools, field test equipment, wiring testers, and maintenance support systems. These solutions cater to manufacturers, suppliers, integrators, and operators within the aerospace, defense, energy, and rail sectors both domestically and internationally.

HR Path is a global consultancy focused on human capital management, with a team of over 500 consultants operating across North America, Europe, and the Middle East. The company specializes in HR Systems Integration, HR Outsourcing, and HR Business Consulting, offering a range of services to support businesses in their digital transformation. HR Path is an authorized reseller of various HR software solutions, including those from SAP, SuccessFactors, and Oracle HCM, among others. In addition to reselling, the company has developed its own HR software solutions, such as BiHRdy, a business intelligence tool; Pandore, a packaged HR, payroll, and time management solution; and Geef, a talent management system. The client portfolio includes a mix of large corporations, including CAC 40-listed companies, as well as small and medium-sized enterprises and public sector organizations, reflecting its versatility in meeting diverse client needs.

Tournus Equipement, S.A.S. is a manufacturer based in Tournus, France, specializing in stainless steel environments for professional kitchens and supermarket fish counters. Established in 1910, the company provides a wide range of products, including mobile and modular professional kitchens, regeneration ovens, warmers, sterilizing cabinets, dishwashing equipment, and various stainless steel furniture and shelving solutions. Its offerings also encompass self-service lines for meal distribution, custom equipment, and accessories such as wash-basins, gutters, floor drains, trolleys, and containers. Tournus Equipement serves diverse sectors, including canteens in companies and schools, restaurants, hotels, bakeries, supermarkets, and transport catering services. The company is committed to delivering durable and customizable solutions tailored to meet the specific needs of its clients.

Verbraeken Infra NV is a Belgian company specializing in the construction and renovation of underground and overhead infrastructure networks across Europe and North Africa. Founded in 1966 and based in Temse, Belgium, the company provides a wide range of services, including earth and roadworks, pipeline and sewer installation, and electrical works such as the installation of underground transmission cables and public lighting maintenance. Verbraeken Infra also engages in the installation of traditional copper and coaxial cables, as well as advanced techniques like horizontal directional drilling and pipe jacking. With approximately 1,000 employees and annual sales of €140 million, the company has expanded its operations in France, Germany, and the Benelux region, strengthening its market position in Belgium and enhancing its capacity to serve gas, water, electricity, and telecom companies.

Arvelle Therapeutics GmbH is a biopharmaceutical company headquartered in Zug, Switzerland, founded in 2019. The company is dedicated to developing and commercializing innovative treatments for patients suffering from central nervous system (CNS) disorders. Its primary focus is on cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients experiencing focal seizures. Through its efforts, Arvelle Therapeutics seeks to enhance the quality of care available to individuals affected by debilitating neurological and neuromuscular diseases.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

HighLife is a medical technology company specializing in Transcatheter Mitral Valve Replacement (TMVR) aimed at treating mitral valve regurgitation. Founded in 2010 by Georg Börtlein, the company is developing a minimally invasive prosthetic mitral valve designed to be implanted on a beating heart, allowing for the preservation of the native valve structure and surrounding anatomy. HighLife's innovative system facilitates a transseptal delivery through the femoral vein, enabling a reversible approach that minimizes trauma to patients during surgical procedures. The technology is currently undergoing clinical evaluation, with a focus on ensuring ease and safety of use for healthcare providers.

Atlantic Therapeutics Limited is a medical technology company based in Galway, Ireland, with additional offices in London, Paris, and Salem. Established in 2013, the company specializes in the manufacture and distribution of medical devices designed for pelvic floor muscle strengthening and nerve stimulation. Its key products include Innovotherapy, a device aimed at enhancing pelvic floor muscle function, and INNOVO, a wearable device specifically targeting stress urinary incontinence by addressing its underlying causes. Atlantic Therapeutics distributes its products through a network of distributors across Ireland, the United Kingdom, France, Germany, and the Middle East. The company operates as a subsidiary of Bio-Medical Research Limited.

Lease Protect France SAS is a company based in Marseille, France, specializing in the installation, servicing, and maintenance of video surveillance and security systems. Founded in 2009, it offers a variety of products, including anti-theft gates, closed-circuit televisions, fog generators, and electronic plotters. The company focuses on addressing shrinkage concerns, particularly for small and medium-sized businesses, by providing tailored solutions that leverage advanced technology. Its extensive network includes offices in multiple locations across France, allowing for local proximity and responsive service. Additionally, Lease Protect offers innovative financing solutions to support its clients in implementing effective security measures.

Exciva GmbH, founded in 2015 and headquartered in Heidelberg, Germany, focuses on developing innovative therapies for dementia and related diseases. The company operates a targeted drug rescue program aimed at pharmaceutical research and development, specifically designed to create symptomatic and disease-modifying treatments. Exciva specializes in addressing both the neurological and psychological aspects of behavioral and psychological symptoms associated with dementia. Its approach involves rescuing and repurposing approved drugs for new indications and uses, thereby providing valuable solutions to the healthcare industry. Through its comprehensive program, Exciva seeks to improve treatment options and outcomes for patients suffering from dementia.

Solware Group is a software publisher and integrator focused on providing innovative and scalable solutions for the medico-social and automotive sectors. The company develops robust enterprise software tailored to the specific needs of medical facilities and auto garages, enhancing operational efficiency and addressing daily challenges faced by its clients. By delivering adaptable software, Solware Group aims to improve the business operations of its users, ensuring that they can effectively navigate the complexities of their respective industries.

Atlantic Therapeutics Limited is a medical technology company based in Galway, Ireland, with additional offices in London, Paris, and Salem. Established in 2013, the company specializes in the manufacture and distribution of medical devices designed for pelvic floor muscle strengthening and nerve stimulation. Its key products include Innovotherapy, a device aimed at enhancing pelvic floor muscle function, and INNOVO, a wearable device specifically targeting stress urinary incontinence by addressing its underlying causes. Atlantic Therapeutics distributes its products through a network of distributors across Ireland, the United Kingdom, France, Germany, and the Middle East. The company operates as a subsidiary of Bio-Medical Research Limited.

Bioclinic operates a network of medical analysis laboratories in the Ile-de-France region, serving health professionals, hospitals, clinics, care centers, and retirement homes. Founded in 1995 and based in Paris, the company specializes in areas such as molecular biology, genetics, antibiotic resistance, and reproductive health. By focusing on these fields, Bioclinic aims to provide clients and their patients with enhanced medical diagnostic results.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Groupe Joryf is a specialized construction group based in Ile-de-France, focusing on the housing market. The company provides a range of construction and engineering services, including in-house structural work and masonry. It undertakes various projects, encompassing collective housing, single-family homes, offices, tourist hotels, student accommodations, and residences for the elderly. By offering comprehensive services tailored to diverse housing needs, Groupe Joryf plays a significant role in the regional construction landscape.

Platinum Invest group specializes in jewelry production for luxury brands.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

Skill & You is the leading provider of vocational e-learning in France, focusing on delivering real results and recognized qualifications such as BAC PRO, BEP, BP, BTS, and CAP. The company operates an online education and distance learning platform that offers customized courses tailored to the specific needs of learners and industries. By leveraging innovative pedagogy and adaptable educational technology, Skill & You empowers individuals to acquire professional skills necessary for career advancement or personal development. With a strong track record of successful educational initiatives, Skill & You is committed to addressing the challenges of employment by equipping learners with the skills needed to transform their lives.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

Orbility is a provider of off-street parking applications and programs aimed at enhancing the efficiency of transportation systems. The company specializes in developing automated fare-collection systems, real-time passenger information systems, vehicle tracking and management solutions, and intelligent transport management systems. Its comprehensive parking assistance tools give clients, which include airports, shopping centers, municipalities, and both public and private operators, complete operational and management control over their car parking systems. By offering these innovative solutions, Orbility supports clients in improving the effectiveness of their parking and transportation services.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2014 by scientists from the Infectiology Research Center. The company focuses on drug discovery and development for the treatment of acute and chronic viral infections, utilizing a unique platform to identify intracellular therapeutic targets and molecules. ENYO Pharma is developing a pipeline of drug candidates addressing various indications, including hepatitis B virus, nonalcoholic steatohepatitis, and oncology. Its lead compound, EYP001, is designed to modulate specific nuclear receptors, aiming to reduce viral reservoirs and inhibit harmful viral protein expression. The company is also advancing EYP002 through preclinical studies. ENYO Pharma collaborates closely with established research institutions and aims to conduct its molecules into Phase II clinical trials, striving to become a global leader in antiviral therapeutics.

TRiCares is a medical device company focused on creating innovative solutions for tricuspid valve regurgitation. The company specializes in developing a catheter-based valve replacement system that facilitates minimally invasive treatments for patients suffering from tricuspid insufficiency. By emphasizing anatomical conformation and user-friendly design, TRiCares aims to provide effective and durable treatment options that improve patient outcomes. Through its advancements in medical technology, TRiCares addresses a critical need in cardiology, enhancing the quality of care for those affected by this condition.

Crescendo Biologics Limited is a clinical-stage biotechnology company based in Cambridge, United Kingdom, specializing in the development of innovative therapies for oncology and dermatology. The company focuses on creating multi-specific immune-oncology modulators and Humabody Drug Conjugates using its proprietary transgenic mouse platform. This technology allows for the in vivo maturation of human VH domains, optimizing their affinity and biophysical properties for therapeutic use. Crescendo Biologics aims to address critical challenges in generating high-affinity, soluble human VH antibody fragments, which are recognized for their potential as effective therapeutics. By leveraging its advanced platforms, the company is engaged in the product development of in-house targets as well as collaborations with other organizations to enhance the efficacy of cancer treatments. Founded in 2007 and originally known as Translocus Limited, Crescendo Biologics has established itself as a leader in the field of next-generation antibody therapeutics.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

BIOGROUP-LCD, a major French player in local medical biology, supports more than 20,000 patients every day and offers more than 2000 routine and specialized daily examinations, based on performance and technological innovation. Partner at every moment between the patient and the medical profession, your laboratory participates in the screening, diagnosis, monitoring and prognosis of the most common pathologies to the most demanding, throughout your course of care. BIOGROUP-LCD develops for this purpose all its human and technological resources. The team of qualified, qualified medical biologists follows continuous and regular training.

Walor is a leading European manufacturer specializing in high-precision mechanical parts, primarily serving the automotive and energy sectors. With 12 production sites across five countries and a workforce of approximately 1,600 employees, the company focuses on the design, production, and assembly of forgings and machined components, including parts for engines, gearboxes, and steering systems. Walor is recognized for its ability to meet stringent market and technical requirements, ensuring quality, cost-effectiveness, and capacity in the production of automotive mechanical components. Its clientele includes some of the largest manufacturers, system operators, and automotive suppliers in the industry.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.

TimeOne, established in 2016, is a global marketing services group formed by merging Public-Idées and Place des Leads. Headquartered in France with operations across Europe, Asia, South Africa, and South America, the company specializes in providing comprehensive digital marketing solutions. TimeOne's core offerings include programmatic advertising, native content marketing, performance-based campaigns, digital marketplace management, publishing services, and mobile marketing strategies. The company is renowned for its innovative approach to prescriptive marketing, driven by a robust data management platform (DMP) and a strong focus on research and development.

GLOBE Groupe sa is a Paris-based advertising agency that specializes in strategic marketing and communication services. The company focuses on shopper marketing to create impactful consumer experiences that drive sales. It offers a range of services including strategic planning, non-media planning, talent casting, recruitment, training, payroll, and logistics such as storage, dispatch, and cold-chain management. GLOBE Groupe also implements marketing activation campaigns and provides tools for performance measurement, utilizing key performance indicators to assess the effectiveness of its strategies. The firm caters to various sectors including consumer goods, media, retail, and recruitment, ensuring that its clients can adapt to the evolving landscape of consumer behavior and promotional messaging. Through its secure online platform, myGLOBE, clients can monitor operations in real-time, enhancing transparency and communication throughout the marketing process.

La Vie Saine is a retailer based in Montgolfier, France, specializing in organic and ecological products. Founded in 1952 and headquartered in Dijon, the company offers a diverse range of items, including dairy products, fruits, vegetables, groceries, bakery items, meat, and wine. In addition to these, La Vie Saine provides specialized foods such as eggs, poultry, health foods, spices, herbs, as well as coffee and tea. The company also features certified ecological cosmetic products for babies and children, alongside organic cosmetics, grains, and cereals. La Vie Saine is committed to ensuring the quality of its offerings by sourcing products made from natural ingredients.

Loyalty Company is a marketing and communication consultancy that focuses on enhancing business performance through the integration of data and technology. The firm specializes in customer marketing, sales promotion, and branding services, utilizing a combination of data-driven insights, creative strategies, and technological expertise. By prioritizing customer-centric approaches, Loyalty Company aims to help clients build profitable and enduring relationships with their customers, ultimately driving brand strength and business success.

Allodiagnostic SAS is a company based in Paris, France, specializing in real estate diagnostics for private individuals during the rental or sale of properties. Established in 2001, it provides essential assessments, including termite inspections, electrical evaluations, and energy performance ratings. As the first expert network for mandatory real estate diagnostics in France, Allodiagnostic serves both individual clients and real estate professionals, offering tailored solutions to meet various diagnostic needs. The company has operated as a subsidiary of Edmond de Rothschild (France) since July 2017.

Intech is a leading manufacturer of orthopedic instruments and implants dedicated to enhancing patient outcomes. Operating with a workforce of around 1,000 employees globally, the company provides comprehensive manufacturing solutions to medical device original equipment manufacturers (OEMs). Intech specializes in a wide range of surgical tools, including implants, sterilization cases, and trays, catering to various medical fields such as spine, hip, knee, sports medicine, and trauma surgery. With facilities located in the United States, France, and Malaysia, Intech is positioned as a one-stop shop for medical device OEMs, delivering both off-the-shelf and custom-made instruments efficiently and cost-effectively.

Complexa, Inc. is a biopharmaceutical company focused on developing innovative medicines for severe and life-threatening conditions related to fibrosis and inflammation. Founded in 2008 and based in Berwyn, Pennsylvania, the company specializes in researching endogenous human cell signaling technologies to address a range of inflammatory, fibrotic, and central nervous system diseases. Its proprietary technology centers on the synthesis and therapeutic use of endogenous nitro-fatty acids, which serve as cell-signaling agents that modulate key inflammatory pathways. Notable among its developments is CXA-10, an oral nitrated fatty acid compound aimed at treating conditions such as focal segmental glomerulosclerosis and pulmonary arterial hypertension. Through its research efforts, Complexa aims to enhance existing anti-inflammatory and metabolic signaling mechanisms to support the resolution and repair of both acute and chronic tissue injuries.

Sarawak Group is a media and marketing services company based in Boulogne-Billancourt, France. It specializes in establishing sales, merchandising, and brand activation services aimed at enhancing the performance of its clients' products and services. The company provides a range of offerings, including business-to-business sales, retail sales force support, point-of-sale solutions, event animation, and brand promotion. Its clientele includes small shops, large department stores, and retail companies, reflecting its capability to cater to diverse market needs. Through these services, Sarawak Group seeks to drive sales results and improve brand visibility for its customers.

Studia S.A.S. is a consultancy firm based in Meyreuil, France, specializing in enterprise content management (ECM) and document engineering. Founded in 2009, the company provides a range of services, including implementation advice, strategic consulting, digital data processing support, and risk control. Studia also focuses on digital transition and business support, catering to sectors such as energy, rail transport, aeronautics, defense, and tertiary/public industries. The firm is recognized for its expertise in managing the production, flow, valuation, digitization, dissemination, and archiving of physical and digital documents. By helping clients identify, value, and secure sensitive data, Studia enables organizations to enhance their documentary heritage and effectively manage their content needs.

Groupe 3S SAS, founded in 2001 and based in Roissy-en-France, France, specializes in providing a comprehensive range of ground handling and airport management services. The company offers essential services to airlines and airport operators, including passenger and baggage handling, load control, ramp activities, and crew management. Additionally, Groupe 3S delivers airport services such as assistance for persons with disabilities, management of taxi areas, cleaning of airports, aircraft de-icing, and runway maintenance. The organization also engages in industrial cleaning, ultra-cleanliness, facility management, and home support services for individuals. Moreover, it provides aviation security training, dangerous goods handling, and ground handling training courses. Through the synergy of expertise from its subsidiaries, Groupe 3S has established itself as a prominent player in the global services market.